Owens & Minor sets 2028 targets: revenue >$12B, adj. EPS >$3.50, 20%+ CAGR

ACCENDRA HEALTH INC/VA/

2028 revenue target exceeding $12 billion; adjusted EBITDA above $750 million.
Adjusted EPS target >$3.50, representing a CAGR of more than 20% from 2024 to 2028.
Cumulative free cash flow between 2024-2028 expected to exceed $1.3 billion.
Patient Direct segment expected to outpace the market and strengthen home-based care position.
Plan includes margin optimization in Products & Healthcare Services and disciplined capital allocation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.